Diabetes affects an estimated 537 million adults worldwide, a number projected to rise dramatically in the coming decades [[3]]. While frequently enough discussed as a condition requiring careful blood sugar management, emerging research is revealing potential benefits of a long-standing diabetes medication, metformin, beyond glycemic control. A new study indicates that women with Type 2 diabetes taking metformin had a significantly lower risk of mortality before age 90, prompting further examination into its potential anti-aging properties and sparking a large-scale clinical trial to explore its broader applications.
Millions of families navigate the daily challenges of conditions that often go unacknowledged, and diabetes is among them. Nathalie Doisy, communications director at the French Diabetes Federation, is keenly aware of the silence surrounding the disease: “Diabetes is an excess of sugar in the blood, a chronic hyperglycemia. The body no longer produces enough insulin or doesn’t use it properly. Diabetes isn’t curable, but it can be managed.” Behind the sometimes-burdensome routine, however, lie encouraging advancements. Understanding that diabetes isn’t a single condition is key, as it presents in different forms. Type 1 diabetes is an autoimmune disease that often affects young people, while Type 2, accounting for over 90% of cases, typically develops after age 40 – though diagnoses are increasingly occurring in younger individuals. Currently, 3.5 million people in France are being treated for diabetes, and an estimated 700,000 are living with the condition undiagnosed. Approximately 400 new cases are diagnosed each day. Despite these figures, a long-standing medication may offer a new approach to managing the disease.
Diabetes: A Daily Condition That’s Never Benign
When discussing diabetes with the Institut Paris Région, Nathalie Doisy frequently emphasizes a factor many prefer to overlook: the significant impact of lifestyle. “A sedentary lifestyle, screen time, and eating meals on the go… all of these contribute to weight gain, which in turn increases the risk of Type 2 diabetes,” she explains. This paints a familiar picture: children snacking while using tablets, adults grabbing lunch between meetings, and evenings too short for regular physical activity.
As a result, the numbers are rising, and the potential complications – including blindness, foot problems, and heart problems – are serious. The situation is particularly concerning in certain areas, such as the French overseas territories and Seine-Saint-Denis, highlighting the connection between socioeconomic hardship and diabetes rates. The French Diabetes Federation is working to change perceptions through prevention campaigns, World Diabetes Day events, and educational programs. The goal is to inform, reassure, and, most importantly, raise awareness. While the disease itself may be silent, its consequences are rarely subtle.
Metformin: A Common Drug Generating New Scientific Interest
Metformin is a widely prescribed medication, often described as “invisible” due to its common use. Prescribed for 60 years to regulate blood sugar, it doesn’t initially appear revolutionary. However, Science et Vie reports that this molecule is now attracting attention beyond diabetes care. A joint American and German research team analyzed data from the Women’s Health Initiative, a large-scale study that has followed participants for three decades.
Researchers compared two groups of women over 60, all recently diagnosed with Type 2 diabetes: those who started metformin and those who took sulfonylureas. The results surprised even experts: women taking metformin had a 30% lower risk of dying before age 90 compared to those treated with other medications. The study, published in May 2025 in The Journal of Gerontology, is based on more than 15 years of follow-up. Its methodology, a “target trial” designed to mimic a randomized controlled trial, strengthened the validity of the findings. This research offers a potential new avenue for improving longevity and quality of life for individuals with Type 2 diabetes.
An Old Drug, Novel Effects
The growing interest in metformin stems from its multifaceted effects. According to researchers cited by ScienceAlert, the drug reduces oxidative stress, limits chronic inflammation, stimulates genes associated with longevity – such as FOXO3 – and may even protect DNA. Studies on animal models have shown even more dramatic results: mice living longer, delayed tumor development, and improved cognitive function.
The enthusiasm has led to the development of a large clinical trial, TAME (Targeting Aging with Metformin), to test the molecule’s effects on age-related diseases. While the project is still awaiting funding, it demonstrates the seriousness with which the question is being considered. However, scientists caution against over-optimism. The study doesn’t prove that metformin increases lifespan; it establishes a correlation, not a certainty. The study’s limitations – including the lack of a placebo group, the focus solely on postmenopausal women, and the difficulty of controlling for all external factors – necessitate considerable caution.
